| Literature DB >> 34619078 |
Nadja Leimer1, Xiaoqian Wu1, Yu Imai1, Madeleine Morrissette1, Norman Pitt1, Quentin Favre-Godal1, Akira Iinishi1, Samta Jain1, Mariaelena Caboni1, Inga V Leus2, Vincent Bonifay2, Samantha Niles1, Rachel Bargabos1, Meghan Ghiglieri1, Rachel Corsetti1, Megan Krumpoch1, Gabriel Fox1, Sangkeun Son1, Dorota Klepacki3, Yury S Polikanov4, Cecily A Freliech5, Julie E McCarthy5, Diane G Edmondson6, Steven J Norris6, Anthony D'Onofrio1, Linden T Hu5, Helen I Zgurskaya2, Kim Lewis7.
Abstract
Lyme disease is on the rise. Caused by a spirochete Borreliella burgdorferi, it affects an estimated 500,000 people in the United States alone. The antibiotics currently used to treat Lyme disease are broad spectrum, damage the microbiome, and select for resistance in non-target bacteria. We therefore sought to identify a compound acting selectively against B. burgdorferi. A screen of soil micro-organisms revealed a compound highly selective against spirochetes, including B. burgdorferi. Unexpectedly, this compound was determined to be hygromycin A, a known antimicrobial produced by Streptomyces hygroscopicus. Hygromycin A targets the ribosomes and is taken up by B. burgdorferi, explaining its selectivity. Hygromycin A cleared the B. burgdorferi infection in mice, including animals that ingested the compound in a bait, and was less disruptive to the fecal microbiome than clinically relevant antibiotics. This selective antibiotic holds the promise of providing a better therapeutic for Lyme disease and eradicating it in the environment.Entities:
Keywords: B. burgdorferi; Lyme disease; Spirochetes; antibiotic; microbiome; transport
Mesh：
Substances：
Year: 2021 PMID： 34619078 PMCID： PMC8526400 DOI： 10.1016/j.cell.2021.09.011
Source DB: PubMed Journal: Cell ISSN： 0092-8674 Impact factor: 66.850